Black Box Biotechnology B B B Black BoxBiotechnology
Cagrilintide + Semaglutide 2 sizes RESEARCH USE ONLY BLACK BOX BIOTECHNOLOGY · CS5

Cagrilintide + Semaglutide

Also known as: CagriSema blend · Amylin + GLP-1 combination
Metabolic & GLP-1 Blend In stock Box of 10 vials 3 references

Co-formulated amylin analogue and GLP-1 agonist in a single vial — the CagriSema research model.

Black Box Biotechnology Cagrilintide Black Box Biotechnology Semaglutide

Available sizes

SKUPer vialPack
CS5 5 mg (2.5 + 2.5) 10 vials / box
CS10 10 mg (5 + 5) 10 vials / box

Order Cagrilintide + Semaglutide

Pricing is quoted directly and is competitive at every tier — message us with the SKUs you want and quantities for a quote.

Quote on Telegram Quote on Signal

Replies within 36 hours. Cryptocurrency (preferred) or card / money-app with a processing fee. COA for this batch available on request.

This blend co-formulates cagrilintide and semaglutide in a 1:1 ratio, mirroring the combination under investigation as CagriSema. The two mechanisms are complementary: semaglutide engages the GLP-1 receptor 3 while cagrilintide engages amylin/calcitonin receptors 2.

In a phase 1b trial of the combination, cagrilintide 2.4 mg with semaglutide 2.4 mg produced a mean body-weight change of −17.1% at 20 weeks versus −9.8% with semaglutide alone 1.

At a glance

  • 1:1 cagrilintide : semaglutide
  • Available as 2.5 mg + 2.5 mg or 5 mg + 5 mg per vial
  • Single reconstitution for combination-mechanism studies
Research use only. All products are sold strictly for laboratory research and development purposes. They are not intended for human or veterinary use, diagnosis, treatment, cure or prevention of any disease. Not for human consumption. Summaries above describe published findings in laboratory and clinical research models and do not constitute claims about this product.
Form
Lyophilized powder
Purity
HPLC-verified — Certificate of Analysis available on request
Pack size
Box of 10 vials
Storage
Lyophilized: −20 °C, protected from light (2–8 °C short-term). Reconstituted: 2–8 °C.

Sequence, formula and CAS data are provided for identification. Batch-specific purity, mass-spec and HPLC data are on the Certificate of Analysis — ask for it with your order.

  1. Enebo LB, Berthelsen KK, Kankam M, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet. 2021;397(10286):1736-1748.
    doi:10.1016/S0140-6736(21)00845-X PubMed 33894838
  2. Lau DCW, Erichsen L, Francisco AM, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet. 2021;398(10317):2160-2172.
    doi:10.1016/S0140-6736(21)01751-7 PubMed 34798060
  3. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002.
    doi:10.1056/NEJMoa2032183 PubMed 33567185

Citations retrieved from PubMed (NCBI). Links open the publisher record via DOI and the PubMed abstract.

Related

Often ordered together

More in Metabolic
Quote on Telegram